Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti–Aquaporin-4 Antibody–Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results From the Global NMO SPOTLIGHT Registry

2025 U.S. Update of Meningococcal Infection Incidence & Outcomes in Eculizumab or Ravulizumab Patients with Generalized Myasthenia Gravis or Neuromyelitis Optica Spectrum Disorder in Clinical Practice

Gene Expression Signatures Associated with Prior Rituximab Treatment in Patients with Anti–Aquaporin-4 Antibody–Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the CHAMPION-NMOSD Trial

Characterization of Antibiotic Prophylaxis Risk Mitigation Practices Across Eculizumab and Ravulizumab Adult, Phase III Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromy